Clinical course of hypertrophic cardiomyopathy patients implanted with a transvenous or subcutaneous defibrillator

被引:9
|
作者
Francia, Pietro [1 ]
Ziacchi, Matteo [2 ]
Adduci, Carmen [1 ]
Ammendola, Ernesto [3 ]
Pieragnoli, Paolo [4 ]
De Filippo, Paolo [5 ]
Rapacciuolo, Antonio [6 ]
Rella, Valeria [7 ]
Migliore, Federico [8 ]
Viani, Stefano [9 ]
Musumeci, Maria Beatrice [1 ]
Biagini, Elena [2 ]
Lovecchio, Mariolina [10 ]
Baldini, Rossella [1 ]
Falasconi, Giulio [11 ,12 ]
Autore, Camillo [1 ]
Biffi, Mauro [2 ]
Cecchi, Franco [4 ,7 ]
机构
[1] Univ Sapienza, St Andrea Hosp, Dept Clin & Mol Med, Cardiol, Rome, Italy
[2] Univ Bologna, Inst Cardiol, Dept Expt Diagnost & Specialty Med, Policlin S Orsola Malpighi, Bologna, Italy
[3] Univ Campania Luigi Vanvitelli, Monaldi Hosp, Dept Translat Med Sci, Naples, Italy
[4] Univ Florence, Careggi Univ Hosp, Florence, Italy
[5] Papa Giovanni XXIII Hosp, Bergamo, Italy
[6] Univ Naples Federico II, Dept Adv Biomed Sci, Naples, Italy
[7] San Luca Hosp, Ist Auxol Italiano, Dept Cardiovasc Neural & Metab Sci, IRCCS, Milan, Italy
[8] Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Padua, Italy
[9] Univ Hosp Pisa, Cardiothorac & Vasc Dept, Cardiol Div 2, Pisa, Italy
[10] Boston Sci, Milan, Italy
[11] Univ Barcelona, Campus Clin, Barcelona, Spain
[12] IRCCS Humanitas Res Hosp, Milan, Italy
来源
EUROPACE | 2023年 / 25卷 / 09期
关键词
Hypertrophic cardiomyopathy; Implantable cardioverter-defibrillator; Subcutaneous implantable cardioverter-defibrillator; Device-related complications; SUDDEN CARDIAC DEATH; CARDIOVERTER-DEFIBRILLATOR; TASK-FORCE; INAPPROPRIATE SHOCKS; EUROPEAN-SOCIETY; PREVENTION; OUTCOMES; THERAPY; ICD; ASSOCIATION;
D O I
10.1093/europace/euad270
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims The implantable cardioverter-defibrillator (ICD) is a life-saving therapy in patients with hypertrophic cardiomyopathy (HCM) at risk of sudden cardiac death. Implantable cardioverter-defibrillator complications are of concern. The subcutaneous ICD (S-ICD) does not use transvenous leads and is expected to reduce complications. However, it does not provide bradycardia and anti-tachycardia pacing (ATP). The aim of this study was to compare appropriate and inappropriate ICD interventions, complications, disease-related adverse events and mortality between HCM patients implanted with a S- or transvenous (TV)-ICD.Methods and results Consecutive HCM patients implanted with a S- (n = 216) or TV-ICD (n = 211) were enrolled. Propensity-adjusted cumulative Kaplan-Meier curves and multivariate Cox proportional hazard ratios were used to compare 5-year event-free survival and the risk of events. The S-ICD patients had lower 5-year risk of appropriate (HR: 0.32; 95%CI: 0.15-0.65; P = 0.002) and inappropriate (HR: 0.44; 95%CI: 0.20-0.95; P = 0.038) ICD interventions, driven by a high incidence of ATP therapy in the TV-ICD group. The S- and TV-ICD patients experienced similar 5-year rate of device-related complications, albeit the risk of major lead-related complications was lower in S-ICD patients (HR: 0.17; 95%CI: 0.038-0.79; P = 0.023). The TV- and S-ICD patients displayed similar risk of disease-related complications (HR: 0.64; 95%CI: 0.27-1.52; P = 0.309) and mortality (HR: 0.74; 95%CI: 0.29-1.87; P = 0.521).Conclusion Hypertrophic cardiomyopathy patients implanted with a S-ICD had lower 5-year risk of appropriate and inappropriate ICD therapies as well as of major lead-related complications as compared to those implanted with a TV-ICD. Long-term comparative follow-up studies will clarify whether the lower incidence of major lead-related complications will translate into a morbidity or survival benefit. Graphical Abstract
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Subcutaneous versus transvenous implantable defibrillator in patients with hypertrophic cardiomyopathy
    Jankelson, Lior
    Garber, Leonid
    Sherrid, Mark
    Massera, Daniele
    Jones, Paul
    Barbhaiya, Chirag
    Holmes, Douglas
    Knotts, Robert
    Bernstein, Scott
    Spinelli, Michael
    Park, David
    Aizer, Anthony
    Chinitz, Larry
    HEART RHYTHM, 2022, 19 (05) : 759 - 767
  • [2] Subcutaneous and Transvenous Defibrillator in Arrhythmogenic Right Ventricular Cardiomyopathy
    Wang, Weijia
    Gasperetti, Alessio
    Sears, Samuel
    Tichnell, Crystal
    Murray, Brittney
    Tandri, Harikrishna S.
    James, Cynthia
    Calkins, Hugh G.
    CIRCULATION, 2022, 146
  • [3] Subcutaneous versus transvenous implantable cardioverter defibrillator in hypertrophic cardiomyopathy: a systematic review and meta-analysis
    Menezes Junior, Antonio da Silva
    Oliveira, Izadora Caiado
    de Sousa, Andre Maroccolo
    Piai, Ricardo Figueiredo Paro
    Oliveira, Vinicius Martins Rodrigues
    CARDIOVASCULAR DIAGNOSIS AND THERAPY, 2024, 14 (03) : 318 - 327
  • [4] Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy
    Francia, Pietro
    Adduci, Carmen
    Palano, Francesca
    Semprini, Lorenzo
    Serdoz, Andrea
    Montesanti, Dalma
    Santini, Daria
    Musumeci, Beatrice
    Salvati, Adriano
    Volpe, Massimo
    Autore, Camillo
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2015, 26 (08) : 893 - 899
  • [5] Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience
    Weinstock, Jonathan
    Bader, Yousef H.
    Maron, Martin S.
    Rowin, Ethan J.
    Link, Mark S.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (02):
  • [6] The need for a subsequent transvenous system in patients implanted with subcutaneous implantable cardioverter-defibrillator
    Gasperetti, Alessio
    Schiavone, Marco
    Vogler, Julia
    Laredo, Mikael
    Fastenrath, Fabian
    Palmisano, Pietro
    Ziacchi, Matteo
    Angeletti, Andrea
    Mitacchione, Gianfranco
    Kaiser, Lukas
    Compagnucci, Paolo
    Breitenstein, Alexander
    Arosio, Roberto
    Vitali, Francesco
    De Bonis, Silvana
    Picarelli, Francesco
    Casella, Michela
    Santini, Luca
    Pignalberi, Carlo
    Lavalle, Carlo
    Pisano, Ennio
    Ricciardi, Danilo
    Calo, Leonardo
    Curnis, Antonio
    Bertini, Matteo
    Gulletta, Simone
    Dello Russo, Antonio
    Badenco, Nicolas
    Tondo, Claudio
    Kuschyk, Juergen
    Tilz, Roland
    Forleo, Giovanni B.
    Biffi, Mauro
    HEART RHYTHM, 2022, 19 (12) : 1958 - 1964
  • [7] Impairment of Quality of Life in Patients with Implanted Subcutaneous Cardioverter Defibrillator (S-ICD) Compared to Implanted Transvenous Cardioverter Defibrillator Therapy
    Thienel, Manuela
    Haum, Magda
    Sadoni, Sebastian
    Novotny, Julia
    Estner, Heidi L.
    Fichtner, Stephanie
    Lackermair, Korbinian
    PATIENT PREFERENCE AND ADHERENCE, 2022, 16 : 3027 - 3033
  • [8] The subcutaneous defibrillator will replace the transvenous defibrillator
    Crozier, Ian
    JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2011, 32 (01) : 73 - 77
  • [9] The subcutaneous defibrillator will replace the transvenous defibrillator
    Ian Crozier
    Journal of Interventional Cardiac Electrophysiology, 2011, 32 : 73 - 77
  • [10] Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy
    Maurizi, Niccolo
    Tanini, Ilaria
    Olivotto, Iacopo
    Amendola, Ernesto
    Limongelli, Giuseppe
    Losi, Maria Angela
    Allocca, Giuseppe
    Perego, Giovanni Battista
    Pieragnoli, Paolo
    Ricciardi, Giuseppe
    De Filippo, Paolo
    Ferrari, Paola
    Quarta, Giovanni
    Viani, Stefano
    Rapacciuolo, Antonio
    Bongiorni, Maria Grazia
    Cecchi, Franco
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 231 : 115 - 119